companydata.dkcompanydata.dk

Ascendis Pharma Growth Disorders A/S: Financial statements 2013

CVR: 32323677

Source: annual report 2013, Danish Business Authority

01/01/2013 – 31/12/2013

Ascendis Pharma Growth Disorders A/S (CVR 32323677) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -22,831 and a net result of DKK -33,146. Equity in the 2013 report amounted to DKK 89,025. The solvency ratio was 7.3%.

Gross Profit
DKK -22,831
Profit/Loss
DKK -33,146
Equity
DKK 89,025
Total Assets
DKK 1,217,830

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2013

ACP 30.06.2012 4 A/S changes name to ASCENDIS PHARMA RELAXIN DIVISION A/SNov 28, 2013

On November 28, 2013, the company changed its name from ACP 30.06.2012 4 A/S to ASCENDIS PHARMA RELAXIN DIVISION A/S.

Ascendis Pharma Growth Disorders A/S publishes interim reportJun 24, 2013

Ascendis Pharma Growth Disorders A/S has published its interim report for the period June 29, 2012 to December 31, 2012.

About Ascendis Pharma Growth Disorders A/S

Ascendis Pharma Growth Disorders A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ASCENDIS PHARMA, CIRCULATORY DISEASES DIVISION A/S and ASCENDIS PHARMA RELAXIN DIVISION A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR -190,726,000 and a net result of EUR -225,725,000 compared with EUR -176,019,000 the year before. Equity in the 2025 report amounted to EUR -723,740,000.

Source: annual report 2025, Danish Business Authority